Study on the relationship between blood zinc levels and the maintenance of kidney function

Association of Serum Zinc Levels with Renal Functional Stability and Long-term Prognosis: A Retrospective Cohort Study - Zinc-Renal Stability Study

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000060675

Enrollment

2400

Registered

2026-02-16

Start date

2026-02-10

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Kidney Disease (CKD), Diabetic Kidney Disease (DKD), Hypertensive Nephrosclerosis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who meet all of the following criteria: 1. Serum zinc levels were measured at the Department of Endocrinology and Metabolism between January 1, 2015, and December 31, 2023. 2. Follow-up eGFR data are available for at least 1.5 years after the date of the first serum zinc measurement (baseline). 3. eGFR was measured at least three times after the baseline date.

Exclusion criteria

Exclusion criteria: Patients who meet any of the following criteria: 1. Receiving dialysis therapy (hemodialysis or peritoneal dialysis) or having undergone kidney transplantation at baseline. 2. Diagnosed with active malignancy at baseline (excluded from the primary analysis). 3. Received zinc supplementation (e.g., zinc acetate, polaprezinc) during the follow-up period (excluded from the primary analysis of natural clinical course).

Design outcomes

Primary

Measure	Time frame
The long-term decline rate of estimated glomerular filtration rate (eGFR slope: mL/min/1.73m^2/year) calculated using a linear mixed model (LMM) during a follow-up period of up to 10 years (minimum 1.5 years) from the date of the first serum zinc measurement (baseline).	—

Secondary

Measure	Time frame
1. Coefficient of variation (CV) calculated from the residuals after removing the trend (decline) from the longitudinal eGFR trajectory during the follow-up period of up to 10 years. 2. Time to the first occurrence of a composite renal event (initiation of renal replacement therapy, sustained decline in eGFR of 40% or more from baseline, doubling of serum creatinine, or fatal/non-fatal cardiovascular events). 3. Time to the first hospitalization due to acute kidney injury (AKI). 4. Proportion of patients exhibiting a rapid decline in eGFR slope of -5 mL/min/1.73m^2/year or -3 mL/min/1.73m^2/year or steeper during the follow-up period. 5. Time to all-cause mortality.	—

Measure

Time frame

1. Coefficient of variation (CV) calculated from the residuals after removing the trend (decline) from the longitudinal eGFR trajectory during the follow-up period of up to 10 years. 2. Time to the first occurrence of a composite renal event (initiation of renal replacement therapy, sustained decline in eGFR of 40% or more from baseline, doubling of serum creatinine, or fatal/non-fatal cardiovascular events). 3. Time to the first hospitalization due to acute kidney injury (AKI). 4. Proportion of patients exhibiting a rapid decline in eGFR slope of -5 mL/min/1.73m^2/year or -3 mL/min/1.73m^2/year or steeper during the follow-up period. 5. Time to all-cause mortality.

—

Countries

Japan

Contacts

Public ContactYoshihiro Hayashi

Shimane University Faculty of Medicine Internal Medicine 1

yoshayashi@med.shimane-u.ac.jp+81-853-20-2183

Outcome results